



Five Prime Therapeutics, Inc.  
Investor Relations Department  
111 Oyster Point Blvd.  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: FPRX <sup>1</sup>

Last Trade:	22.01
Trade Time:	2:50 PM ET Monday, January 22, 2018
Change:	0.05  (0.228%)
Day Range	21.75 - 22.71
52-Week Range	19.73 - 49.30
Volume	252,136
Market Cap. (\$M)	636.749
Shares Out (M)	28.930

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immunoncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Monday, January 8, 2018*  
[Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time](#)

*Wednesday, January 3, 2018*  
[Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150](#)

*Wednesday, January 3, 2018*  
[Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference](#)

*Tuesday, January 2, 2018*  
[Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer](#)

*Tuesday, December 19, 2017*  
[Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Third Quarter Financial Results](#)

*Friday, February 24, 2017*  
[Annual Report \(10-K\)](#)

*Friday, March 31, 2017*  
[Definitive Proxy Statement](#)

*Monday, November 6, 2017*  
[Quarterly Report \(10-Q\)](#)

*Tuesday, August 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

